Similar Papers

Paper Title
Journal
Date
Author
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Roberto De Icco ... Sara Bottiroli
The Journal of Headache and Pain | VOL. 23
Roberto De Icco, et. al.Roberto De Icco ... Sara Bottiroli
17 Sep 2022
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
Gregor Broessner ... Uwe Reuter
Headache | VOL. 60
Gregor Broessner, et. al.Gregor Broessner ... Uwe Reuter
26 Aug 2020
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Peter J Goadsby ... Koen Paemeleire
Cephalalgia | VOL. 39
Peter J Goadsby, et. al.Peter J Goadsby ... Koen Paemeleire
13 Apr 2019
Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
Messoud Ashina ... Leonidas Lyras
Cephalalgia | VOL. 43
Messoud Ashina, et. al.Messoud Ashina ... Leonidas Lyras
01 Nov 2023
View more papers

More From: Neurology

Paper Title
Journal
Date
Author
Reader Response: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Calixto Machado
Neurology | VOL. -
Calixto MachadoCalixto Machado
28 Jan 2025
Brain Hypertrophy in Patients With Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis and Its Clinical Correlates
Richard Zubal ... Marian Galovic
Neurology | VOL. 104
Richard Zubal, et. al.Richard Zubal ... Marian Galovic
28 Jan 2025
Reader Response: Wall-Eyed Bilateral Internuclear Ophthalmoplegia Variant Syndrome Caused by Isolated Left Thalamic Infarction.
Eric R Eggenberger
Neurology | VOL. 104
Eric R EggenbergerEric R Eggenberger
28 Jan 2025
Editors' Note: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Aravind Ganesh ... Steven L Galetta
Neurology | VOL. -
Aravind Ganesh, et. al.Aravind Ganesh ... Steven L Galetta
28 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.